PDS Biotechnology logo

PDS BiotechnologyNASDAQ: PDSB

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

30 September 2015

Next earnings report:

27 March 2025

Last dividends:

N/A

Next dividends:

N/A
$75.75 M
-80%vs. 3y high
41%vs. sector
-vs. 3y high
-vs. sector
-61%vs. 3y high
72%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | 65 min ago
$2.02-$0.06(-3.11%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

PDSB Latest News

Down -35.74% in 4 Weeks, Here's Why PDS Biotechnology (PDSB) Looks Ripe for a Turnaround
zacks.com20 November 2024 Sentiment: POSITIVE

The heavy selling pressure might have exhausted for PDS Biotechnology (PDSB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

PDS Biotechnology Corporation (PDSB) Q3 2024 Earnings Call Transcript
seekingalpha.com14 November 2024 Sentiment: POSITIVE

PDS Biotechnology Corporation (NASDAQ:PDSB ) Q3 2024 Earnings Conference Call November 14, 2024 8:30 AM ET Company Participants Tom Johnson - LifeSci Advisors Frank Bedu-Addo - Chief Executive Officer Lars Boesgaard - Chief Financial Officer Kirk Shepard - Chief Medical Officer Conference Call Participants Louise Chen - Cantor Fitzgerald Ali Rashidfarrokhi - B. Riley Robert LeBoyer - Noble Capital Markets Operator Good morning ladies and gentlemen and welcome to PDS Biotech's Third Quarter 2024 Results and Clinical Strategy Update Conference Call.

PDS Biotechnology (PDSB) Upgraded to Strong Buy: Here's What You Should Know
zacks.com22 October 2024 Sentiment: POSITIVE

PDS Biotechnology (PDSB) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

PDS Biotechnology Corporation (PDSB) Q4 2023 Earnings Call Transcript
Seeking Alpha27 March 2024 Sentiment: NEUTRAL

PDS Biotechnology Corporation (PDSB) Q4 2023 Earnings Call Transcript

All You Need to Know About PDS Biotechnology (PDSB) Rating Upgrade to Buy
Zacks Investment Research02 January 2024 Sentiment: POSITIVE

PDS Biotechnology (PDSB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

PDS Biotechnology Corporation (PDSB) Q3 2023 Earnings Call Transcript
Seeking Alpha14 November 2023 Sentiment: POSITIVE

PDS Biotechnology Corporation (NASDAQ:PDSB ) Q3 2023 Earnings Call Transcript November 14, 2023 8:00 AM ET Company Participants Nicole Jones - Investor Relations Frank Bedu-Addo - Chief Executive Officer Matthew Hill - Chief Financial Officer Conference Call Participants Louise Chen - Cantor Fitzgerald Mayank Mamtani - B. Riley Securities Joe Pantginis - HC Wainwright Laura Suriel - Alliance Resource Partners Operator Greetings and welcome to the PDS Biotechnology Third Quarter 2023 Earnings Call and Webcast.

PDS Biotech's (PDSB) Shares Up 12% in a Month: Here's Why
Zacks Investment Research29 August 2023 Sentiment: POSITIVE

Shares of PDS Biotech (PDSB) show an upward trajectory as the company progresses toward initiating the late-stage development of its lead pipeline candidate.

PDS Biotechnology: Interim Data Reinforces Push Towards Phase 3 Study
Seeking Alpha14 August 2023 Sentiment: POSITIVE

PDS Biotechnology has achieved positive results in its phase 2 study of PDS0101 in combination with Merck's Keytruda for HPV16-positive head and neck cancer. The interim analysis showed 9 confirmed responses, which increased to 14 in a later update, surpassing the efficacy threshold for the study. PDS plans to submit an amended IND application to the FDA in Q3 2023 to initiate its phase 3 VERSATILE-003 study.

The Prognosis For PDS Biotechnology
Seeking Alpha13 August 2023 Sentiment: POSITIVE

PDS Biotechnology Corporation has had a volatile stock performance in recent years. The company has made slow and steady progress advancing its pipeline and is well-liked within the analyst firm community. With two registrational studies on the horizon, it seems a good time to 'circle back' on this small developmental, oncology-focused concern.

PDS Biotechnology Post-ASCO Conference Call Tomorrow, June 6, at 8 a.m. ET
GlobeNewsWire05 June 2023 Sentiment: POSITIVE

FLORHAM PARK, N.J., June 05, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced that the Company will be hosting a conference call and webcast tomorrow, June 6, 2023, to discuss the promising interim data from the VERSATILE-002 (NCT04260126) Phase 2 clinical trial investigating PDS0101 in combination with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), presented at the 2023 American Society for Clinical Oncology (ASCO) meeting.

What type of business is PDS Biotechnology?

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey.

What sector is PDS Biotechnology in?

PDS Biotechnology is in the Healthcare sector

What industry is PDS Biotechnology in?

PDS Biotechnology is in the Biotechnology industry

What country is PDS Biotechnology from?

PDS Biotechnology is headquartered in United States

When did PDS Biotechnology go public?

PDS Biotechnology initial public offering (IPO) was on 30 September 2015

What is PDS Biotechnology website?

https://www.pdsbiotech.com

Is PDS Biotechnology in the S&P 500?

No, PDS Biotechnology is not included in the S&P 500 index

Is PDS Biotechnology in the NASDAQ 100?

No, PDS Biotechnology is not included in the NASDAQ 100 index

Is PDS Biotechnology in the Dow Jones?

No, PDS Biotechnology is not included in the Dow Jones index

When was PDS Biotechnology the previous earnings report?

No data

When does PDS Biotechnology earnings report?

The next expected earnings date for PDS Biotechnology is 27 March 2025